<?xml version='1.0' encoding='utf-8'?>
<document id="23875253"><sentence text="Acitretin exhibits inhibitory effects towards UDP-glucuronosyltransferase (UGT)1A9-mediated 4-methylumbelliferone (4-MU) and propofol glucuronidation reaction."><entity charOffset="0-9" id="DDI-PubMed.23875253.s1.e0" text="Acitretin" /><entity charOffset="92-113" id="DDI-PubMed.23875253.s1.e1" text="4-methylumbelliferone" /><entity charOffset="115-119" id="DDI-PubMed.23875253.s1.e2" text="4-MU" /><entity charOffset="125-133" id="DDI-PubMed.23875253.s1.e3" text="propofol" /><pair ddi="false" e1="DDI-PubMed.23875253.s1.e0" e2="DDI-PubMed.23875253.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23875253.s1.e0" e2="DDI-PubMed.23875253.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23875253.s1.e0" e2="DDI-PubMed.23875253.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23875253.s1.e0" e2="DDI-PubMed.23875253.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23875253.s1.e1" e2="DDI-PubMed.23875253.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23875253.s1.e1" e2="DDI-PubMed.23875253.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23875253.s1.e1" e2="DDI-PubMed.23875253.s1.e3" /><pair ddi="false" e1="DDI-PubMed.23875253.s1.e2" e2="DDI-PubMed.23875253.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23875253.s1.e2" e2="DDI-PubMed.23875253.s1.e3" /></sentence><sentence text="The present study aimed to evaluate the potential risk of drug-drug interactions associated with acitretin which is a drug for therapy of psoriasis approved by the Food and Drug Administration (FDA)"><entity charOffset="97-106" id="DDI-PubMed.23875253.s2.e0" text="acitretin" /></sentence><sentence text=" The initial screening of acitretin's inhibition towards 4-methylumbelliferone (4-MU) glucuronidation catalyzed by important UDP-glucuronosyltransferase (UGT) isoforms in the liver showed that UGT1A9 activity was strongly inhibited by acitretin with other UGT isoforms negligibly influenced"><entity charOffset="57-78" id="DDI-PubMed.23875253.s3.e0" text="4-methylumbelliferone" /><entity charOffset="80-84" id="DDI-PubMed.23875253.s3.e1" text="4-MU" /><entity charOffset="235-244" id="DDI-PubMed.23875253.s3.e2" text="acitretin" /><pair ddi="false" e1="DDI-PubMed.23875253.s3.e0" e2="DDI-PubMed.23875253.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23875253.s3.e0" e2="DDI-PubMed.23875253.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23875253.s3.e0" e2="DDI-PubMed.23875253.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23875253.s3.e1" e2="DDI-PubMed.23875253.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23875253.s3.e1" e2="DDI-PubMed.23875253.s3.e2" /></sentence><sentence text=" The inhibition type is best fit to competitive inhibition, and the inhibition kinetic parameter (K(i)) was determined to be 3" /><sentence text="5 microM" /><sentence text=" The inhibition behaviour of acitretin towards UGT1A9 activity did not exhibit probe substrate-dependent behaviour when selecting human liver microsomes (HLMs)-catalyzed propofol-O-glucuronidation as probe reaction of UGT1A9"><entity charOffset="29-38" id="DDI-PubMed.23875253.s6.e0" text="acitretin" /></sentence><sentence text=" The same inhibition type and similar inhibition parameters (K(i) = 3" /><sentence text="2 microM) were obtained" /><sentence text=" Using the maximum plasma exposure dose of acitretin (C(max)), the C(max)/K(i) values were calculated to be 0"><entity charOffset="43-52" id="DDI-PubMed.23875253.s9.e0" text="acitretin" /></sentence><sentence text="23 and 0" /><sentence text="25 when selecting 4-MU and propofol as probe substrates, respectively"><entity charOffset="18-22" id="DDI-PubMed.23875253.s11.e0" text="4-MU" /><entity charOffset="27-35" id="DDI-PubMed.23875253.s11.e1" text="propofol" /><pair ddi="false" e1="DDI-PubMed.23875253.s11.e0" e2="DDI-PubMed.23875253.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23875253.s11.e0" e2="DDI-PubMed.23875253.s11.e1" /></sentence><sentence text=" All these results indicate a potential clinical drug-drug interaction between acitretin and 4-MU or propofol"><entity charOffset="79-88" id="DDI-PubMed.23875253.s12.e0" text="acitretin" /><entity charOffset="93-97" id="DDI-PubMed.23875253.s12.e1" text="4-MU" /><entity charOffset="101-109" id="DDI-PubMed.23875253.s12.e2" text="propofol" /><pair ddi="false" e1="DDI-PubMed.23875253.s12.e0" e2="DDI-PubMed.23875253.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23875253.s12.e0" e2="DDI-PubMed.23875253.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23875253.s12.e0" e2="DDI-PubMed.23875253.s12.e2" /><pair ddi="false" e1="DDI-PubMed.23875253.s12.e1" e2="DDI-PubMed.23875253.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23875253.s12.e1" e2="DDI-PubMed.23875253.s12.e2" /></sentence><sentence text="" /></document>